Source: http://www.google.com/patents/US8163726?dq=7,453,150
Timestamp: 2014-07-22 10:27:37
Document Index: 670397504

Matched Legal Cases: ['Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 03', 'Application No. 03', 'Application No. 2004']

Patent US8163726 - Administering to the mammal with the angiogenesis-mediated disease or ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsThe present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening...http://www.google.com/patents/US8163726?utm_source=gb-gplus-sharePatent US8163726 - Administering to the mammal with the angiogenesis-mediated disease or condition an amount effective to inhibit, reduce, or prevent angiogenesis of an immunophilin binding active agent, e.g., rapamycin, a rapamycin analog, or tacrolimus ; diabetic retinopathy, macular degenerationAdvanced Patent SearchPublication numberUS8163726 B2Publication typeGrantApplication numberUS 10/665,203Publication dateApr 24, 2012Filing dateSep 18, 2003Priority dateSep 18, 2002Also published asCA2498191A1, CA2498191C, EP1539157A2, EP1539157A4, EP1539157B1, EP2514420A2, EP2514420A3, US8618088, US20050187241, US20090036479, US20120190705, WO2004027027A2, WO2004027027A3Publication number10665203, 665203, US 8163726 B2, US 8163726B2, US-B2-8163726, US8163726 B2, US8163726B2InventorsRong Wen, Zhijun Luo, Alan M. LatiesOriginal AssigneeUniversity Of PennsylvaniaExport CitationBiBTeX, EndNote, RefManPatent Citations (87), Non-Patent Citations (33), Classifications (11), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetAdministering to the mammal with the angiogenesis-mediated disease or condition an amount effective to inhibit, reduce, or prevent angiogenesis of an immunophilin binding active agent, e.g., rapamycin, a rapamycin analog, or tacrolimus ; diabetic retinopathy, macular degenerationUS 8163726 B2Abstract The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5011844Aug 25, 1989Apr 30, 1991Sandoz Ltd.Substituted 4-azatricyclo(22.3.1.04,9)octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing themUS5078999Feb 22, 1991Jan 7, 1992American Home Products CorporationMethod of treating systemic lupus erythematosusUS5100899Jun 6, 1989Mar 31, 1992Roy CalneMethods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereofUS5189042Aug 22, 1991Feb 23, 1993Merck & Co. Inc.Fluoromacrolides having immunosuppressive activityUS5192773Jul 2, 1990Mar 9, 1993Vertex Pharmaceuticals, Inc.Immunosuppressive compoundsUS5258389Nov 9, 1992Nov 2, 1993Merck & Co., Inc.O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivativesUS5368865Jul 27, 1993Nov 29, 1994Fujisawa Pharmaceutical Co., Ltd.Suspendible composition and process for preparing the sameUS5378475Feb 21, 1991Jan 3, 1995University Of Kentucky Research FoundationSustained release drug delivery devicesUS5387589 *Nov 17, 1992Feb 7, 1995University Of Louisville Research Foundation, Inc.Administering rapamycinUS5457111Nov 9, 1993Oct 10, 1995Abbott LaboratoriesMacrocyclic immunomodulatorsUS5514686Apr 24, 1992May 7, 1996Fujisawa Pharmaceutical Co., Ltd.Use of macrolide compounds for eye diseasesUS5516770Sep 22, 1994May 14, 1996American Home Products CorporationRapamycin formulation for IV injectionUS5527907Oct 26, 1994Jun 18, 1996Abbott LaboratoriesMacrolide immunomodulatorsUS5530006Mar 7, 1994Jun 25, 1996American Home Products CorporationRapamycin formulation for IV injectionUS5532248May 12, 1995Jul 2, 1996Merck Co., Inc.O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activityUS5559121May 23, 1995Sep 24, 1996American Home Products CorporationRapamycin formulations for oral administrationUS5601844Nov 11, 1993Feb 11, 1997Fujisawa Pharmaceutical Co., Ltd.Sustained release medicinal preparationUS5616588Sep 12, 1994Apr 1, 1997American Home Products CorporationRapamycin formulation for IV injectionUS5621108Dec 5, 1994Apr 15, 1997Trustees Of The University Of PennsylvaniaProcesses and intermediates for preparing macrocyclesUS5672605Apr 19, 1995Sep 30, 1997Abbott LaboratoriesMacrolide immunomodulatorsUS5773019Sep 27, 1995Jun 30, 1998The University Of Kentucky Research FoundationInner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer coating layer that is permeable to the low solubility agentUS5800807 *Jan 29, 1997Sep 1, 1998Bausch & Lomb IncorporatedOphthalmic compositions including glycerin and propylene glycolUS5883082Nov 23, 1994Mar 16, 1999Isis Pharmaceuticals, Inc.Compositions and methods for preventing and treating allograft rejectionUS6015815Sep 24, 1998Jan 18, 2000Abbott LaboratoriesMacrolide immunomodulators.US6254860Apr 13, 1999Jul 3, 2001Allergan Sales, Inc.Ocular treatment using cyclosporin-A derivativesUS6329386Nov 2, 1999Dec 11, 2001Abbott LaboratoriesTetrazole-containing rapamycin analogs with shortened half-livesUS6376517Aug 14, 1998Apr 23, 2002Gpi Nil Holdings, Inc.For treating vision loss, preventing vision degeneration, and promoting vision regeneration (?neopsis?)US6387918Feb 18, 1998May 14, 2002Fujisawa Pharmaceutical Co., Ltd.A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseasesUS6399629Jul 1, 1998Jun 4, 2002Microcide Pharmaceuticals, Inc.Efflux pump inhibitorsUS6440990May 23, 1997Aug 27, 2002Novartis AgO-alkylated rapamycin derivatives and their use, particularly as immunosuppressantsUS6482802May 11, 1999Nov 19, 2002Endowment For Research In Human Biology, Inc.Use of neomycin for treating angiogenesis-related diseasesUS6534693Jan 31, 2001Mar 18, 2003Afmedica, Inc.Surgically implanted devices having reduced scar tissue formationUS6576224May 25, 2000Jun 10, 2003Sinuspharma, Inc.Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitisUS6632836Oct 21, 1999Oct 14, 2003Merck & Co., Inc.To treat autoimmune disorders, cardiac arrhythmias and the likeUS6699493Nov 28, 2001Mar 2, 2004Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use thereforUS6713081Mar 15, 2001Mar 30, 2004The United States Of America As Represented By The Department Of Health And Human ServicesFor controlled/sustained release; corneal allograft therapy; age-related macular degenerationUS6812220Aug 28, 2002Nov 2, 2004University Of British ColumbiaPharmaceutical compositions and methods relating to fucansUS6872383Jan 30, 2003Mar 29, 2005Sucampo AgAdministering macrolactone antibiotic KF-506US6890546Sep 10, 2001May 10, 2005Abbott LaboratoriesStents, catheters, arterio-venous grafts, by-pass grafts and drug delivery ballons with surface coating containing a rapamycin derivative having a tetrazole groupUS20020123505Sep 10, 2001Sep 5, 2002Mollison Karl W.Stents, catheters, arterio-venous grafts, by-pass grafts and drug delivery ballons with surface coating containing a rapamycin derivative having a tetrazole groupUS20030018044Sep 19, 2002Jan 23, 2003Peyman Gholam A.Treatment of ocular diseaseUS20030027744Apr 18, 2002Feb 6, 2003Dana M. RezaUse of a CD40:CD154 binding interruptor to treat immunological complications of the eyeUS20030031631Aug 28, 2002Feb 13, 2003Osbakken Robert S.Having surface tension, effective for therapy of respiratory systme disordersUS20030069560May 2, 2002Apr 10, 2003Massachusetts Eye And Ear InfirmaryImplantable drug delivery device and use thereofUS20030077297Feb 11, 2002Apr 24, 2003Feng-Jing ChenPharmaceutical formulations and systems for improved absorption and multistage release of active agentsUS20030190286Aug 29, 2002Oct 9, 2003Dugger Harry A.Propellant free buccal spray composition for transmucosal administration of pharmacologically active compound comprising 0.001-60 percent by weight immunosuppressants, mucolytics, glucocorticoids and 30-99 percent polar solventUS20040018228May 7, 2003Jan 29, 2004Afmedica, Inc.Compositions and methods for reducing scar tissue formationUS20040057958May 19, 2003Mar 25, 2004Waggoner David W.Immunogenicity-enhancing carriers and compositions thereof and methods of using the sameUS20040092435Nov 7, 2002May 13, 2004Peyman Gholam A.Treatment of ocular diseaseUS20040167152Jul 25, 2003Aug 26, 2004WyethMixture of a rapamycin compound with cosolvent and antioxidantUS20040234611Sep 13, 2002Nov 25, 2004Marklus AhlheimActive material embedded into biocompatible polymer or lipidUS20050025810Jul 31, 2003Feb 3, 2005Gholam PeymanTreatment of ocular diseaseUS20050048123Jun 25, 2004Mar 3, 2005Control Delivery System, Inc.In situ gelling drug delivery systemUS20050123605Oct 7, 2004Jun 9, 2005Angiotech Pharmaceuticals, Inc.Anticancer agents; prevent forming blood vessels; removal blockageEP0041745A1May 12, 1981Dec 16, 1981SADEPAN CHIMICA S.p.A.Urea-formaldehyde resin based adhesive containing calcium and/or ammonium ligninsulphonate as additive, a urea-formaldehyde resin modified with calcium and/or ammonium ligninsulphonate, and methods for the production thereof, for preparing agglomerated wood panelsEP0041795B1May 27, 1981Jan 16, 1985Ayerst, Mckenna And Harrison Inc.Injectable composition of rapamycinJP2002522485A * Title not availableWO1993019763A1Mar 29, 1993Oct 14, 1993American Home ProdRapamycin formulation for iv injectionWO1994021642A1Mar 11, 1994Sep 29, 1994Abbott LabMacrocyclic amide and urea immunomodulatorsWO1996041865A1Jun 7, 1996Dec 27, 1996Ariad Gene Therapeutics IncRapamcycin-based regulation of biological eventsWO1997010806A1Sep 18, 1996Mar 27, 1997Fujisawa Pharmaceutical CoAerosol compositionsWO1997016068A1Oct 28, 1996May 9, 1997Robert K BakerTriterpene derivatives with immunosuppressant activityWO1999020261A2Oct 22, 1998Apr 29, 1999Jens PonikauUse of antigunal agents for the topial treatment of fungus-induced mucositisWO1999022722A2Oct 30, 1998May 14, 1999Abbott LabUse of macrolides for the treatment of cancer and macular degenerationWO1999034830A1Dec 17, 1998Jul 15, 1999Galena AsTopical ophthalmic preparations containing immunosuppressive agentsWO1999037667A1Jan 22, 1999Jul 29, 1999Suzanne ChamberlandEfflux pump inhibitorsWO1999058126A1May 11, 1999Nov 18, 1999Endowment Res Inhuman BiologyUse of neomycin for treating angiogenesis-related diseasesWO2000009109A2Aug 12, 1999Feb 24, 2000Guilford Pharm IncPipecolic acid derivatives for vision and memory disordersWO2000028945A2Oct 12, 1999May 25, 2000Kammen Daniel P VanAnticonvulsant derivatives useful in treating post traumatic stress disorderWO2000038703A1Dec 20, 1999Jul 6, 2000Fujisawa Pharmaceutical CoAgent for treating visual cell function disorderWO2000040089A1Jan 5, 2000Jul 13, 2000Massachusetts Eye And Ear InfiTargeted transscleral controlled release drug delivery to the retina and choroidWO2001030386A1Oct 19, 2000May 3, 2001Burt AdelmanUse of a cd40:cd154 binding interruptor to treat immunological complications of the eyeWO2001042219A2Dec 7, 2000Jun 14, 2001Inotek CorpNovel substituted phenanthridinones and methods of use thereofWO2001047495A1Dec 1, 2000Jul 5, 2001Pfizer Prod IncPharmaceutical compositions providing enhanced drug concentrationsWO2002028387A1Oct 3, 2001Apr 11, 2002Oncopharmaceutical IncInhibitors of angiogenesis and tumor growth for local and systemic administrationWO2002062335A2Jan 16, 2002Aug 15, 2002Vascular Therapies LlcImplantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular graftsWO2002074196A1Mar 14, 2002Sep 26, 2002Us HealthOcular therapeutic agent delivery devices and methods for making and using such devicesWO2003068186A1Feb 11, 2003Aug 21, 2003Lipocine IncPharmaceutical formulations and systems for improved absorption and multistage release of active agentsWO2003074027A2Feb 28, 2003Sep 12, 2003Simon BenitaSelf emulsifying drug delivery systems for poorly soluble drugsWO2003074029A1Mar 7, 2003Sep 12, 2003Nicholas McenteeFast melt multiparticulate formulations for oral deliveryWO2003090684A2Apr 24, 2003Nov 6, 2003Sun Bow Co LtdPolymer compositions containing a macrocyclic triene compoundWO2004019904A1Aug 27, 2003Mar 11, 2004Novadel Pharma IncBuccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthmaWO2004027027A2Sep 18, 2003Apr 1, 2004Univ PennsylvaniaMethod of inhibiting choroidal neovascularizationWO2004028477A2Sep 29, 2003Apr 8, 2004Juan Eugene DeMethods for treatment and/or prevention of retinal diseaseWO2004043480A2Sep 10, 2003May 27, 2004Gholam A PeymanIntraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosaWO2004074445A2Feb 17, 2004Sep 2, 2004Jordan S FridmanModel for studying the role of genes in tumor resistance to chemotherapyWO2005051452A2Nov 22, 2004Jun 9, 2005Angiotech Int AgPolymer compositions and methods for their use* Cited by examinerNon-Patent CitationsReference1"Study of possible anticancer drug reveals new mechanism of gene regulation." NewsRx. Jan. 14, 2003.2Akselband, et al. "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts" Transplantation Proceedings, vol. 23, No. 6. Dec. 1991:p. 2833-2836.3Auricchio, et al. "Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye" Molecular Therapy, Jul. 1, 2002, p. 238-242.4Bainbridge, et al. "Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization." Gene Therapy. 2003:p. 1049-1054.5Canadian Intellectual Property Office-Office Action, Application No. 2,498,191, dated Mar. 15, 2011.6Canadian Intellectual Property Office�Office Action, Application No. 2,498,191, dated Mar. 15, 2011.7Canadian Intellectual Property Office-Office Action, Application No. 2,498,191, dated May 6, 2010.8Canadian Intellectual Property Office�Office Action, Application No. 2,498,191, dated May 6, 2010.9EPO Supplementary Partial European Search Report, for EP Application No. EP 03 75 4653; dated Jul. 18, 2008.10EPO-Invitation to Correct Deficiencies, Application No. 03 754 653.8-1216, dated Jun. 25, 2010.11EPO�Invitation to Correct Deficiencies, Application No. 03 754 653.8-1216, dated Jun. 25, 2010.12Guba, et al. "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor." Nature Medicine. vol. 8. No. 2. Feb. 2002. p. 128-135.13Guba, et al. "Rapamycin inhibits tumor growth and metastasis by antiangiogenesis" Chirurgisches Forum 2001. May 1, 2001: p. 37-39.14Hackstein et al., "Rapamycin inhibits macropinocytosis and mannose receptor-mediated . . .", Blood; vol. 100 No. 3 (1084-1087), Aug. 2002.15Hackstein et al., "Rapamycin inhibits macropinocytosis and mannose receptor�mediated . . .", Blood; vol. 100 No. 3 (1084-1087), Aug. 2002.16 *Hikita, Naofumi, Journal of the Kurume Medical Association, Jan. 1994, vol. 57, No. 1, pp. 176-189, Japan (in Japanese).17Humar, et al. "Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling." The FASEB Journal. vol. 16. Jun. 2002: p. 771-780.18 *Japanese Patent Office Action, Patent Application No. 2004-537893, Mailing Date, Sep. 29, 2009 (English Translation).19 *Kimura, Hideya, Angiogenesis Inhibitors, Atarashii Ganka (New Ophthalmology), Jul. 30, 2001, vol. 18, No. 7, pp. 867-870, Japan (in Japanese).20Kuroki, et al. "Rapamycin Inhibits Retinal and Choroidal Neovascularization in Mice." ARVO 2003 Abstract No. 573. May 4, 2003.21Marsland. "The macrolide immunosuppressants in dermatology: mechanisms of action." Eur. J Dermatol. Nov.-Dec. 2002. p. 618-22.22Olsen, et al. "Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization," Arch. Ophthalmol, vol. 112, pp. 1471-1475, Nov. 1994.23Renau, et al. "Addressing the Stability of C-Capped Dipeptide Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic & Med. Chem. Letters. (2001) 11:663-667.24Renau, et al., "Conformationally-Restricted Analogues of Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic& Med. Chem. Letters. (2003) 13:2755-2758.25Rivera et al., "Long-term regulated expression of growth hormone in mice after intramuscular gene transfer," PNAS; vol. 96: 8657-8662, Jul. 1999.26Shen, et al. "Combined Effect of Cyclosporine and Sirolimus on Improving the Longevity of Recombinat Adenovirus-Mediated Transgene Expression in the Retina." Arch Ophthalol. Jul. 2001. vol. 119. p. 1033-1043.27Simamora, P. et al., "Solubilization of Rapamycin," Int. J. Pharm. 213:25-29, Feb. 1, 2001.28Sloper C. Myra L. et al., Tacrolimus (FK506) in the Treatment of Posterior Uveitis Refractory to Cyclosporine, Ophthalmology, Apr. 1999, pp. 723-728, vol. 106, No. 4.29Stepkowski et al., "Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat," Transplantation, vol. 51:22-26, Jan. 1991.30Treins, et al. "Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway." Journal of Biological Chemistry, Aug. 2, 2002. vol. 277, No. 31 p. 27975-27981.31U.S. Appl. No. 60/503,840, Cooper et al.32Wen, et al. "Rapamycin Inhibits Choroidal Neovascularization" ARVO 2003. Abstract No. 3928 May 7, 2003.33 *Zubilewicz, A., et al., Two Distinct Signalling Pathways are Involved in FGF2-Stimulated Proliferation of Choriocapillary Endothelial Cells: A Comparative Study With VEGF, Mar. 22, 2001, vol. 20, No. 12, pp. 1403-1413 (in English).* Cited by examinerClassifications U.S. Classification514/185, 514/912International ClassificationC12N, A61K31/445, A61K31/555, A61K31/4745Cooperative ClassificationY10S514/912, A61K31/436, A61K31/445European ClassificationA61K31/445, A61K31/436Legal EventsDateCodeEventDescriptionSep 11, 2012CCCertificate of correctionMar 14, 2005ASAssignmentOwner name: UNIVERSITY OF PENNSYLVANIA, PENNSYLVANIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEN, RONG;LUO, ZHIJUN;LATIES, ALAN M.;REEL/FRAME:015900/0032Effective date: 20050104RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google